James Whiteaker
AstraZeneca (United States)(US)
Publications by Year
Research Areas
Tuberculosis Research and Epidemiology, Antibiotic Resistance in Bacteria, Cancer therapeutics and mechanisms, Biochemical and Molecular Research, Bacterial Genetics and Biotechnology
Most-Cited Works
- → The Resistome of Pseudomonas aeruginosa in Relationship to Phenotypic Susceptibility(2014)279 cited
- → Azaindoles: Noncovalent DprE1 Inhibitors from Scaffold Morphing Efforts, Kill Mycobacterium tuberculosis and Are Efficacious in Vivo(2013)161 cited
- → Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC(2015)125 cited
- → Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis(2017)124 cited
- → 4-Aminoquinolone Piperidine Amides: Noncovalent Inhibitors of DprE1 with Long Residence Time and Potent Antimycobacterial Activity(2014)94 cited
- → Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in Neisseria gonorrhoeae(2014)94 cited
- → Lead Optimization of 1,4-Azaindoles as Antimycobacterial Agents(2014)89 cited
- → Small-Molecule Inhibitors of Gram-Negative Lipoprotein Trafficking Discovered by Phenotypic Screening(2015)82 cited
- → Diarylthiazole: An Antimycobacterial Scaffold Potentially Targeting PrrB-PrrA Two-Component System(2014)47 cited
- → Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint forStaphylococcus aureus: the role of PBP2a in the activity of ceftaroline(2015)45 cited